Drugmakers seeking to register a biosimilar product in Singapore should provide complete information on the development, control and manufacture of the drug and its active ingredient, a new guidance says. Comparability studies between the biosimilar product and its reference product also must be submitted, the Health Sciences Authority says in the guidance posted on its website on 1 August 2009.
Singapore outlines process to register biosimilars
Home/Guidelines
|
Posted 16/10/2009
0
Post your comment
The guidance document describes the basic principles of a similar biological product, as well as the procedures and requirements for registration of a similar biological product.
The document is intended to:
- introduce the concept of similar biological products
- outline the basic principles to be applied for similar biological products
- describe the procedure and documentary requirements for submitting an application for a similar biological product
- describe the pharmacovigilance requirements for similar biological products
- describe the post-approval batch release requirements for similar biological products
The guidance document is adapted mainly from the EMEA guidelines on similar biological products, with consideration of Singapore’s local regulatory environment.
References:
FDAnews Drug Daily Bulletin Vol. 6 No. 188, 28 September 2009. Singapore outlines process to register biosimilars.
Guidance on registration of similar biological products in Singapore, August 2009.
Source: FDAnews Drug Daily Bulletin
Policies & Legislation
ANVISA and DINAVISA sign MoU to strengthen border surveillance and regulatory cooperation
Congress pushes biosimilar bills as interchangeability concerns linger
Reports
Central America moves toward joint evaluation of biosimilar medicines
The US$52 billion question: can the US keep biosimilars competitive?
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
Related content
Brazil's ANVISA updates guidance on pharmacokinetic studies for biosimilars
Canada eliminates phase III trial requirement for biosimilar approvals
FDA updates draft biosimilar guidance, signalling greater flexibility for developers
FDA finalizes Guidance on Promotional Labeling and Advertising for biologicals
Related content
Brazil's ANVISA updates guidance on pharmacokinetic studies for biosimilars
Home/Guidelines Posted 20/08/2026
Canada eliminates phase III trial requirement for biosimilar approvals
Home/Guidelines Posted 22/06/2026
FDA updates draft biosimilar guidance, signalling greater flexibility for developers
Home/Guidelines Posted 12/06/2026
FDA finalizes Guidance on Promotional Labeling and Advertising for biologicals
Home/Guidelines Posted 25/05/2026
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Post your comment